Day One Biopharmaceuticals, Inc.

NASDAQ:DAWN

14.13 (USD) • At close September 13, 2024
Bedrijfsnaam Day One Biopharmaceuticals, Inc.
Symbool DAWN
Munteenheid USD
Prijs 14.13
Beurswaarde 1,240,055,865
Dividendpercentage 0%
52-weken bereik 9.67 - 18.07
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jeremy Bender M.B.A., Ph.D.
Website https://dayonebio.com

An error occurred while fetching data.

Over Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The

Vergelijkbare Aandelen

Alpha Tau Medical Ltd. logo

Alpha Tau Medical Ltd.

DRTS

2.34 USD

CareMax, Inc. logo

CareMax, Inc.

CMAX

2.04 USD

Rallybio Corporation logo

Rallybio Corporation

RLYB

1.13 USD

Bionano Genomics, Inc. logo

Bionano Genomics, Inc.

BNGO

0.43 USD

Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc.

PRAX

59.88 USD

Adicet Bio, Inc. logo

Adicet Bio, Inc.

ACET

1.49 USD

Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc.

VERA

37.51 USD

908 Devices Inc. logo

908 Devices Inc.

MASS

3.6 USD

Vaxart, Inc. logo

Vaxart, Inc.

VXRT

0.987 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)